Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Puma Biotechnology, Inc.NASDAQ: PBYI

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $1.9M fell 6.4% year over year, ahead of the -13.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 17.3% from the prior quarter. Over 3 fiscal years it compounded at -16.3% a year.

Context

  • Stock-based compensation amounted to 3.0% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -6.4% holds above the trailing-twelve-month pace of -13.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.9M+17.3% QoQ
Last fiscal yearDec 2025
$6.94M-15.8% YoY
LTMMar 2026
$6.81M-13.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.4%——
1 year-15.8%——
3-year CAGR-16.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
6.94M USD
Year-over-year change
-15.8%
4-year CAGR
-32.1%

Stock-Based Compensation vs competitors

How PBYI compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -13.7% is the 8th highest of 11, against a peer median of +23.0%.
  • Stock-based compensation amounts to 3.0% of revenue for PBYI, versus a peer median of 15.6%.
PBYI Competitors
Stock-Based Compensation for PBYI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNGXTango Therapeutics, Inc.LTM Sep 2026$58.58M USD+109.9%+22.9%—
NBPNovaBridge BiosciencesLTM Sep 2025CN¥26.02M CNY+1.1%-74.4%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$25.38M USD+66.4%——
NUVBNuvation Bio Inc.LTM Jun 2026$19.89M USD-153.0%+30.1%11.7%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$15.73M USD+224.1%+209.1%—
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M USD-55.6%-11.3%8.0%
VSTMVerastem, Inc.LTM Mar 2026$9.66M USD+26.4%+15.9%19.5%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$6.81M USD-13.7%-16.3%3.0%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$6.75M CAD+101.1%+21.4%—
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$6.38M USD-39.9%-18.4%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$5.99M USD+19.7%+10.2%1140.6%
Peer median (excluding PBYI) —+23.0%+15.9%15.6%

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(29.13M)2K21.59M30.28M31.11M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
Deferred Income Tax000(7.08M)3.25M
Stock-Based Compensation32.63M11.83M10.25M8.25M6.94M
Change in Working Capital(1.31M)(44.5M)(17.85M)(3.54M)(10.08M)
Accounts Receivables(5.98M)(7.82M)(8.37M)16.35M(21.28M)
Inventory(3.66M)2.58M(2.55M)(1.64M)3.21M
Accounts Payables(902K)(4.73M)449K(1.38M)(453K)
Other Working Capital9.23M(34.52M)(7.38M)(16.86M)8.45M
Other Non-Cash Items7.15M7M1.51M(519K)(358K)
Operating Cash Flow20.65M(15.83M)27.01M38.92M41.8M
Capital Expenditures0(7M)(12.64M)(56K)(71K)
Acquisitions (Net)00000
Purchases of Investments(38.07M)(4.84M)(23.81M)(76.23M)(108.14M)
Sales of Investments27.19M18.94M17.33M55.85M72.02M
Other Investing Activities00(12.5M)00
Investing Cash Flow(10.88M)7.1M(19.13M)(20.44M)(36.19M)
Debt Repayment(1.5M)00(33.33M)(44.44M)
Common Stock Issued012.5M0150K130K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(30.43M)(277K)0(666K)(888K)
Financing Cash Flow(31.93M)12.22M0(33.85M)(45.2M)
Effect of Forex Changes00000
Net Change in Cash(22.16M)3.5M7.88M(15.37M)(39.58M)
Free Cash Flow20.65M(22.83M)14.37M38.86M41.73M

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.